PFS
BLRX

Prospera Financial Services’s BioLineRX BLRX Stock Holding History

Prospera Financial Services’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24
Closed -$2K – 1723
2022
Q1 		$2K Buy
+24
New +$1.67K ﹤0.01% 2454

Other funds holding BLRX

PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prospera Financial Services's BLRX Position: Q2 2022 in Review

Prospera Financial Services sold out of BioLineRX (BLRX) in Q2 2022, closing a stake of 24 shares — an estimated $2K sold.

Prospera Financial Services first reported a position in BLRX in Q1 2022 and held it in 1 quarter. The position peaked at $2K in Q1 2022. 28 funds tracked by Wall St. Rank hold BLRX as of Q2 2022.

  • Prospera Financial Services reported no remaining BioLineRX position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 24 BioLineRX shares in Q2 2022, an estimated $2K.
  • Prospera Financial Services first reported a position in BioLineRX in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's BioLineRX position peaked at $2K in Q1 2022.
  • 28 funds tracked by Wall St. Rank held BioLineRX as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.